Press Releases and News

December 15 2016

New Indications: LANCL2 in Bacterial Infections

BLACKSBURG, VA. December 15, 2016—Lanthionine synthetase C-like 2 (LANCL2) has been validated as a therapeutic target for inflammatory bowel disease (IBD). New research shows that LANCL2[...]

November 15 2016

LANCL2: A Novel Therapeutic Target for Influenza

BLACKSBURG, VA. November 15, 2016—The Landos Biopharma, Inc. (LANDOS) team has recently explored the potential of activating lanthionine synthetase C-like 2 (LANCL2) to treat infectious[...]